Edition:
United States

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
15 Dec 2017
Change (% chg)

$-0.00 (-0.10%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.60
Day's Low
$0.59
Volume
19,379
Avg. Vol
96,327
52-wk High
$1.48
52-wk Low
$0.44

Latest Key Developments (Source: Significant Developments)

Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Aviragen Therapeutics Inc ::AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA.AVIRAGEN THERAPEUTICS INC- ‍EXPECTS TO REPORT TOP-LINE DATA FROM TRIAL IN Q2 OF 2018​.  Full Article

SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction
Thursday, 9 Nov 2017 06:37am EST 

Nov 9 (Reuters) - Aviragen Therapeutics Inc :SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing.SC Fundamental Value Fund LP says intends to vote against Vaxart Inc's proposed transaction.SC Fundamental Value Fund LP reports 6.19 percent stake in Aviragen Therapeutics Inc as of November 7.  Full Article

Aviragen Therapeutics Q1 loss per share $0.14
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Aviragen Therapeutics Inc :Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results.Q1 loss per share $0.14.Q1 revenue $100,000.  Full Article

Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated
Monday, 30 Oct 2017 09:13am EDT 

Oct 30 (Reuters) - Aviragen Therapeutics Inc :On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing.Anticipates incurring about $0.9 million-$1.7 million in total costs associated with job cuts related to Vaxart deal.Company expects to incur the costs during next two quarters through March 31, 2018​.  Full Article

Aviragen Therapeutics and Vaxart enter into merger agreement
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - Aviragen Therapeutics Inc :Aviragen Therapeutics and Vaxart enter into merger agreement.Aviragen Therapeutics Inc - ‍merger will result in a combined company vaxart inc​.Aviragen-‍exchange ratio in deal determined by assigning $60 million in value to Aviragen for financial & clinical assets & $90 million in value for Vaxart's assets​.Aviragen Therapeutics Inc - ‍shares of combined are expected to continue trading on Nasdaq under proposed ticker symbol "VXRT"​.Aviragen Therapeutics Inc - ‍Aviragen will reduce its workforce by six to a total of 10 full-time employees​.Aviragen- ‍on pro forma basis, Vaxart securityholders will own about 60% of combined co, Aviragen securityholders will own about 40% of combined co​.Aviragen Therapeutics Inc - ‍transaction has been approved by board of directors of both companies​.Aviragen Therapeutics Inc - ‍shares of combined are expected to continue trading on Nasdaq under proposed ticker symbol VXRT​.Aviragen-‍Vaxart will be announcing positive results from co's phase 1b open-label, dose-ranging study assessing safety, immunogenicity of VXA-G1.1-NN​.Aviragen Therapeutics Inc - ‍VXA-G1.1-NN met both primary and secondary endpoints for safety and immunogenicity in clinical trial​.Aviragen Therapeutics Inc - ‍phase 2 norovirus challenge study is expected to begin in second half of 2018 for VXA-G1.1-NN​.  Full Article

SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21
Friday, 30 Jun 2017 10:12am EDT 

June 30 (Reuters) - SC Fundamental Value Fund LP::SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing.  Full Article

East Hill Management says Aviragen Therapeutics "should wind up its business and liquidate"
Monday, 19 Jun 2017 05:56pm EDT 

June 19 (Reuters) - Aviragen Therapeutics Inc -:East Hill Management says Aviragen Therapeutics "should abandon all of its plans to explore strategic alternatives and instead should wind up its business and liquidate".East Hill Management says on June 7 had talk with representatives of Aviragen's management and board to discuss, among other things, potential benefit of liquidating the co.East hill management says intend to have further conversations, meetings with management and board of aviragen therapeutics.East hill management and affiliates own 8.8 percent stake in aviragen therapeutics as of June 7 - sec filing.  Full Article

Aviragen Therapeutics Q3 loss per share $0.11
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Aviragen Therapeutics Inc :Aviragen therapeutics reports third quarter fiscal year 2017 financial results.Q3 loss per share $0.11.Q3 revenue $4.9 million versus $5.3 million.Q3 revenue view $3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Aviragen Therapeutics announces review of strategic alternatives
Tuesday, 4 Apr 2017 06:00am EDT 

Aviragen Therapeutics Inc : Company has retained Stifel, Nicolaus & Company, incorporated to serve as its financial advisor in process . Aviragen therapeutics announces review of strategic alternatives and provides corporate update . Does not have a defined timeline for exploration of strategic alternatives . To explore strategic alternatives that include business combination or merger, in-licensing clinical stage programs, deal or other transaction .Aviragen is not confirming that process will result in any strategic alternative being announced or consummated.  Full Article

Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir
Monday, 13 Feb 2017 04:01pm EST 

Aviragen Therapeutics Inc : Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir . Aviragen Therapeutics Inc - SPIRITUS trial did not meet its primary endpoint . Aviragen - Vapendavir did not demonstrate a statistically significant reduction in asthma control questionnaire-6 (ACQ-6) at day 14, primary endpoint . Aviragen - secondary endpoints did not show significant differences between treatment groups and placebo . Aviragen - Vapendavir was shown to be generally well tolerated and safety profile was consistent with previous clinical studies .Aviragen - Vapendavir did not show a significant reduction in asthma control questionnaire-6 for either 264 mg or 528 mg cohorts compared to placebo.  Full Article

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA